Prestige Consumer Healthcare (NYSE:PBH) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a report released on Friday.

Several other research analysts have also weighed in on PBH. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Finally, DA Davidson reissued a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Trading Up 0.1 %

Shares of PBH opened at $76.79 on Friday. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The firm’s fifty day moving average is $80.08 and its two-hundred day moving average is $74.83. Prestige Consumer Healthcare has a 52-week low of $60.00 and a 52-week high of $86.36. The stock has a market cap of $3.79 billion, a PE ratio of 18.68, a price-to-earnings-growth ratio of 2.17 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company’s revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS. Research analysts forecast that Prestige Consumer Healthcare will post 4.46 earnings per share for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now directly owns 18,365 shares of the company’s stock, valued at approximately $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,810 shares of company stock worth $3,187,300. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PBH. JPMorgan Chase & Co. lifted its position in shares of Prestige Consumer Healthcare by 3.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock worth $19,630,000 after buying an additional 8,533 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after purchasing an additional 50,961 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Prestige Consumer Healthcare by 12.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock valued at $708,000 after purchasing an additional 1,120 shares during the last quarter. Barclays PLC boosted its position in shares of Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after purchasing an additional 71,730 shares during the period. Finally, Pinnacle Associates Ltd. grew its stake in Prestige Consumer Healthcare by 60.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company’s stock worth $1,776,000 after buying an additional 9,269 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.